Oral contraceptives and systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 40, Issue 5, 1997, Pages 797-803

  Petri, Michelle ^a   Robinson, Courtland ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY;

DISEASE ACTIVITY; FEMALE FERTILITY; HYPERCOAGULABILITY; OSTEOPOROSIS; OVARY DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; THROMBOSIS;

EID: 0030996961     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780400504     Document Type: Review

References (88)

1. Roubinian J, Talal N, Siiteri PK, Sadakian JA: Sex hormone modulation of autoimmunity in NZB/NZW mice. Arthritis Rheum 22:1162-1169, 1979
2. Steinberg AD, Melez KA, Raveche ES, Reeves JP, Boegel WA, Smathers PA, Taurog JD, Weinlein L, Duvic M: Approach to the study of the role of sex hormones in autoimmunity. Arthritis Rheum 22:1170-1176, 1979
3. Carlsten H, Nilsson N, Jonsson R, Backman K, Holmdahl R, Tarkowski A: Estrogen accelerates immune complex glomerulonephritis but ameliorates T cell-mediated vasculitis and sialoadenitis in autoimmune MRL lpr/lpr mice. Cell Immunol 144:190-202, 1992
4. Petri M, Howard D, Repke J: Frequency of lupus flare in pregnancy: the Hopkins Lupus Pregnancy Center experience. Arthritis Rheum 34:1538-1545, 1991
5. Zulman JI, Talal N, Hoffman GS, Epstein WV: Problems associated with the management of pregnancies in patients with systemic lupus erythematosus. J Rheumatol 7:37-49, 1980
6. Lockshin MD: Pregnancy does not cause systemic lupus erythematosus to worsen. Arthritis Rheum 32:665-670, 1989
7. Lockshin MD, Reinitz E, Druzin ML, Murrman M, Estes D: Lupus pregnancy. I. Case-control prospective study demonstrating absence of lupus exacerbation during or after pregnancy. Am J Med 77:893-898, 1984
8. Urowitz MB, Gladman DD, Farewell VT, Stewart J, McDonald J: Lupus and pregnancy studies. Arthritis Rheum 36:1392-1397, 1993
9. Jara LJ, Lavalle C, Espinoza LR: Does prolactin have a role in the pathogenesis of systemic lupus erythematosus? J Rheumatol 19: 1333-1336, 1992
10. Jara-Quezada L, Graef A, Lavalle C: Prolactin and gonadal hormones during pregnancy in systemic lupus erythematosus. J Rheumatol 18:349-353, 1991
11. McMurray RW, Keisler D, Izui S, Walker SE: Hyperprolactinemia in male NZB/NZW (B/W) F, mice: accelerated autoimmune disease with normal circulating testosterone. Clin Immunol Immunopathol 71:338-343, 1994
12. Petri M, Chan D, Magder L, Goldman D: Longitudinal analysis of prolactin and disease activity in SLE pregnancy (abstract). Arthritis Rheum 38 (suppl 9):S220, 1995
13. Lahita RG, Bucala R, Bradlow HL, Fishman J: Determination of 16 alpha-hydroxyestrone by radioimmunoassay in systemic lupus erythematosus. Arthritis Rheum 28:1122-1127, 1985
14. Tarzy BJ, Garcia CR, Wallach EE, Zweiman B, Myers AR: Rheumatic disease, abnormal serology and oral contraceptives. Lancet 2:501-503, 1972
15. Sanchez-Guerrero J, Liang MH, Karlson EW, Hunter DJ, Colditz GA: Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med 122:430-433, 1995
16. Jungers P, Dougados M, Pélissier C, Kuttenn F, Tron F, Lesavre P, Bach J-F: Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 25:618-623, 1982
17. Julkunen HA: Oral contraceptives in systemic lupus erythematosus: side-effects and influence on the activity of SLE. Scand J Rheumatol 20:427-433, 1991
18. Buyon JP, Kalunian KC, Skovron ML, Petri M, Lahita R, Merrill J, Sammaritano L, Yung C, Licciardi F, Belmont HM, Hahn BH: Can women with systemic lupus erythematosus safely use exogenous estrogens? J Clin Rheumatol 1:205-212, 1995
19. Oral contraceptives, venous thrombosis, and varicose veins: Royal College of General Practitioners' Oral Contraception Study. J R Coll Gen Pract 28:393-399, 1978
20. Vessey MP: Steroid contraception, venous thromboembolism, and stroke: data from countries other than the United States. In, Risks, Benefits, and Controversies in Fertility Control. Edited by JJ Sciarra, GI Zatuchni, JJ Speidel. Hagerstown, MD, Harper & Row, 1978
21. Inman WHW, Vessey MP, Westerholm B, Engelund A: Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. BMJ 2:203-209, 1970
22. Meade TW, Greenberg G, Thompson SG: Progestagens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-μg oestrogen preparations. BMJ 280:1157-1161, 1980
23. Stadel BV: Oral contraceptives and cardiovascular disease (first of two parts). N Engl J Med 305:612-618, 1981
24. Vessey MP, Mant D, Smith A, Yeates D: Oral contraceptives and venous thromboembolism: findings in a large prospective study (abstract). BMJ 292:526, 1986
25. Kay CR: Progestogens and arterial disease: evidence from the Royal College of General Practitioners' study. Am J Obstet Gynecol 142:762-765, 1982
26. Thorogood M, Vessey MP: Trends in use of oral contraceptives in Britain. Br J Fam Plann 16:41-53, 1990
27. Gerstmann BB, Piper JM, Freiman JP, Tomita DK, Kennedy DL, Ferguson WJ, Bennett RC: Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism. Int J Epidemiol 19:931-936, 1990
28. Wells PS, Hirsh J, Anderson DR, Lensing AW, Foster G, Kearon C, Weitz J, D'Ovidio R, Cogo A, Prandoni P: Accuracy of clinical assessment of deep-vein thrombosis. Lancet 345:1326-1330, 1995
29. Poulose KP, Reba RC, Gilday DL, Deland FH, Wagner HN: Diagnosis of pulmonary embolism: a correlative study of the clinical, scan, and angiographic findings, BMJ 3:67-71, 1970
30. Singh K, Viegas OA, Loke D, Ratnam SS: Effect of Norplant-2 rods on liver, lipid and carbohydrate metabolism. Contraception 45:463-472, 1992
31. Singh K, Viegas OA, Loke DF, Ratnam SS: Effect of Norplant implants on liver, lipid and carbohydrate metabolism. Contraception 45:141-153, 1992
32. Singh K, Viegas OA, Loke DF, Ratnam SS: Evaluation of liver function and lipid metabolism following Norplant-2 rods removal. Adv Contracept 9:233-239, 1993
33. Rabe T, Thuro HC, Goebel K, Borchardt C, Grunwald K, Runnebaum B: Lipid metabolism in Norplant-2 users - a two-year follow-up study: total cholesterol, triglycerides, lipoproteins and apolipoproteins. Contraception 45:21-37, 1992
34. Otubu JA, Towobola OA, Aisien AO, Ogunkeye OO: Effects of Norplant contraceptive subdermal implants on serum lipids and lipoproteins. Contraception 47:149-159, 1993
35. Samsioe G: Coagulation and anticoagulation effects of contraceptive steroids. Am J Obstet Gynecol 170:1523-1527, 1994
36. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: A multinational case-control study of cardiovascular disease and steroid hormone contraceptives: description and validation of methods. J Clin Epidemiol 48:1513-1547, 1995
37. Robinson GE: Low-dose combined oral contraceptives. Br J Obstet Gynaecol 101:1036-1042, 1994
38. Speroff L, DeCherney A: Evaluation of a new generation of oral contraceptives. Obstet Gynecol 81:1034-1047, 1993
39. Watt AH: Oral contraceptives and venous thromboembolism (letter). Lancet 346:1430, 1995
40. Nicolaides AN, Irving D: Clinical factors and the risk of deep venous thrombosis. In, Thromboembolism. Edited by AN Nicolaides. London, MTP, 1995
41. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: Venous thromboembolic disease and combined oral contraceptives: results of an international multicentre case-control study. Lancet 346:1575-1582, 1995
42. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C: Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346:1589-1593, 1995
43. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, Macrae KD: Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 312:83-88, 1996
44. Lewis MA, Spitzer WO, Heinemann LAJ, Macrae KD, Bruppacher R, Thorogood M: Third generation oral contraceptives a risk of myocardial infarction: an international case-control study. BMJ 312:88-90, 1996
45. Poulter NR, Parley TMM, Chang CL, Marmot MG, Meirik O: Safety of combined oral contraceptive pills (letter). Lancet 347: 547, 1996
46. Bloemenkamp KWM, Rosendaal FR, Heimerhorst FM, Büller HR, Vandenbroucke JP: Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346: 1593-1596, 1995
47. Villa P, Aznar J, Mira Y, Fernández MA, Vayá A: Third-generation oral contraceptives and low free protein S as a risk for venous thrombosis (letter). Lancet 347:397, 1996
48. Meade TW: Recent developments on the association between oral contraceptives and cardiovascular disease. Adv Drug React Acute Poisoning Rev 1:243-254, 1982
49. Royal College of General Practitioners: Further analysis of mortality in oral contraceptive users. Lancet 1:541-546, 1981
50. Girard M: Thromboembolism and the combined oral contraceptive (letter). Lancet 346:317, 1995
51. Todd GR, McAteer EJ, Jack CM, Maire M, Roberts SD, Buchanan KD: Pulmonary hypertension, systemic lupus erythematosus, and the contraceptive pill. Ann Rheum Dis 44:266-267, 1985
52. Miller MH: Pulmonary hypertension, systemic lupus erythematosus, and the contraceptive pill: another report. Ann Rheum Dis 46:159-161, 1987
53. Sandoval J, Amigo M-C, Barragan R, Izaguirre R, Reyes PA, Martinez-Guerra ML, Palomar A, Gomez A, Garcia-Torres R: Primary antiphospholipid syndrome presenting as chronic thromboembolic pulmonary hypertension: treatment with thromboendarterectomy. J Rheumatol 23:772-775, 1996
54. Asherson RA, Cervera R: Antiphospholipid antibodies and the lung. J Rheumatol 22:62-66, 1995
55. Julkunen HA, Kaaja R, Friman C: Contraceptive practice in women with systemic lupus erythematosus. Br J Rheumatol 32: 227-230, 1993
56. Asherson RA, Harris EN, Hughes GRV, Farquarson RG: Complications of oral contraceptives and antiphospholipid antibodies (letter). Arthritis Rheum 31:575-576, 1988
57. Bruneau C, Intrator L, Sobel A, Beaumont V, Billecocq A: Antibodies to cardiolipin and vascular complications in women taking oral contraceptives (letter). Arthritis Rheum 29:1294, 1986
58. Petri M, Hellmann D, Hochberg M, Meyerhoff J, Bell W, Gold-man D: Arterial thrombotic events in SLE: the Baltimore Lupus Cohort study (abstract). Arthritis Rheum 37 (suppl 9):S297, 1994
59. Petri M, Haffer S, Goldman D: Bimodal pattern of thrombosis in SLE (abstract). Arthritis Rheum 37 (suppl 9):S323, 1994
60. Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK: Stroke in users of low-dose oral contraceptives. N Engl J Med 335:8-15, 1996
61. National Center for Health Statistics Advance Data. Washington, DC, NCHS, vol. 182, 1990
62. Mintz G, Gutierrez C, Deleze M, Rodriquez E: Contraception with progestagens in systemic lupus erythematosus. Contraception 30:29-38, 1984
63. Julkunen H, Kaaja R, Jouhikainen T, Teppo AM, Friman C: Malignant hypertension and antiphospholipid antibodies as presenting features of SLE in a young woman using oral contraceptives. Br J Rheumatol 30:471-472, 1991
64. Yell JA, Burge SM: The effect of hormonal changes on cutaneous disease in lupus erythematosus. Br J Dermatol 129:18-22, 1993
65. Steinberg AD, Steinberg BJ: Lupus disease activity associated with menstrual cycle (letter). J Rheumatol 12:816-817, 1985
66. Petri M, Lim GS, Goldman D: Menstruation and systemic lupus erythematosus (abstract). Arthritis Rheum 35 (suppl 9):S241, 1992
67. Pando JA, Gourley MF, Wilder RL, Crofford LJ: Hormonal supplementation as treatment for cyclical rashes in patients with systemic lupus erythematosus. J Rheumatol 22:2159-2162, 1995
68. Lundström V, Green K, Wiqvist N: Prostaglandins, indomethacin and dysmenorrhea. Prostaglandins 11:893-904, 1976
69. Ekström P, Åkerlund M, Forsling M, Kindahl H, Laudanski T, Mrugacz G: Stimulation of vasopressin release in women with primary dysmenorrhoea and after oral contraceptive treatment effect on uterine contractility. Br J Obstet Gynaecol 99:680-684, 1992
70. Grimes DA, Godwin AJ, Rubin A, Smith A, Lacarra M: Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial. Obstet Gynecol 83:529-533, 1994
71. Petri M: Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. Arthritis Care Res 8:137-145, 1995
72. Lindsay R: The effect of sex steroids on the skeleton in premenopausal women. Am J Obstet Gynecol 166:1993-1996, 1992
73. Boumpas DT, Austin HA III, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741-745, 1992
74. McCune WJ, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox DA: Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 318:1423-1431, 1988
75. Wang CL, Wang F, Bosco JJ: Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 4:11-14, 1995
76. Boumpas DT, Austin HA III, Vaughan EM, Yarboro CH, Klippel JH, Balow JE: Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119:366-369, 1993
77. Chapman RM, Sutcliffe SB: Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. Blood 58:849-851, 1981
78. Glode LM, Robinson J, Gould SF: Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1:1132-1134, 1981
79. Nseyo UO, Huben RP, Klioze SS, Pontes JE: Protection of germinal epithelium with luteinizing hormone-releasing hormone analogue. J Urol 34:187-190, 1985
80. Ataya KM, McKanna JA, Weintraub AM, Clark MR, LeMaire WJ: A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res 45:3651-3656, 1985
81. Chatterjee R, Mills W, Katz M, McGarrigle HH, Goldstone AH: Induction of ovarian function by using short-term human menopausal gonadotropin in patients with ovarian failure following cytotoxic chemotherapy for hematological malignancy. Leuk Lymphoma 10:383-386, 1993
82. Petri M: Gender-based differences in autoimmunity and autoimmune disease. J Wom Health 4:433-436, 1995
83. Travers RL, Hughes GRV: Oral contraceptive therapy and systemic lupus erythematosus. J Rheumatol 5:448-451, 1978
84. Garovich M, Agudelo C, Pisko E: Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum 23:1396-1398, 1980
85. Pimstone B: Systemic lupus erythematosus exacerbated by oral contraceptives. South Afr J Obstet Gynaecol 3:62-63, 1966
86. Hadida M, Sayag J: Lupus érythémateux subanu apparu après une cure du Norfutin chez une malade atteinte de lupus érythémateux chronique. Bull Soc Fr Dermatol Syph 74:616-621, 1968
87. Chapel TA, Burns RE: Oral contraceptives and exacerbation of lupus erythematosus. Am J Obstet Gynecol 110:366-369, 1971
88. Laugier P, Orusco P, Chatelanat F, Humair L, Posternak S: Lupus érythémateux disseminé induit par estrogénes. Bull Soc Fr Dermatol Syph 78:623-628, 1971